info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

X-Linked Hypophosphatemia Companies

X-linked hypophosphatemia (XLH) is a rare genetic disorder characterized by low levels of phosphate in the blood, leading to skeletal abnormalities and other related symptoms. Companies focused on X-linked hypophosphatemia are often involved in developing and providing treatments for this condition.

X-Linked Hypophosphatemia Key CompaniesLatest X-Linked Hypophosphatemia Companies Update



  • July 2022: Ultragenyx Pharmaceutical Inc., a biopharmaceutical company specializing in the development and commercialization of innovative products for severe rare and ultra-rare genetic disorders, announced today the $500 million acquisition by OMERS, one of Canada's largest defined benefit pension plans, of 30% of the company's royalty interest from Kyowa Kirin Co., Ltd on future sales of Crysvita (burosumab) in the United States (U.S.) and Canada. The royalty payment entitlement of OMERS is contingent upon the product's net sales commencing in April 2023. The maximum allowable payment is 1.45 times the purchase price. Crysvita has amassed net sales in excess of $1.3 billion during its initial four years of availability in North America, positioning it as one of the most prosperous product introductions within the rare disease sector. By means of this non-dilutive financing, Ultragenyx strengthens its balance sheet, provides funds for the continuous commercialization of numerous approved medications, and advances its diversified clinical pipeline.



  • Kyowa Kirin, Inc., a subsidiary of the Japanese-based global specialty pharmaceutical company Kyowa Kirin Co., Ltd., will present novel findings in October 2023 that enhance knowledge regarding the clinical attributes and real-life experiences of children, adolescents, and adults afflicted with X-linked hypophosphatemia (XLH), an uncommon genetic metabolic bone disease. Those who have XLH are confronted with the perpetual challenge of disease management and progressively deteriorating morbidities, both of which have detrimental effects on their quality of life. A rare, chronic genetic disorder, X-linked hypophosphatemia can affect the muscles and bones of both infants and adults. In people with XLH, there is insufficient phosphorus storage in the body, an essential mineral for bone health. As a result of the overproduction of fibroblast growth factor 23 (FGF23), an excessive amount of phosphorus is excreted via the urine.


List of X-Linked Hypophosphatemia Key companies in the market

  • Ultragenyx Pharmaceutical

  • Validus Pharmaceuticals LLC

  • Prospec-Tany Technogene Ltd

  • Merck KGaA

  • Zeria Pharmaceutical Co., Ltd

  • Smith & Nephew

  • Narang Medical Limited

  • Eli Lilly and Company

  • F. Hoffmann-La Roche Ltd

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.